Drugs / Emtricitabine-tenofovir disoproxil fumarate
Emtricitabine-tenofovir disoproxil fumarate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01061151 Comparator | Mar 2011 → Sep 2016 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Mixed |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emtricitabine-tenofovir disoproxil fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01061151 ↗ |
| Known as | Truvada [TRV] | “Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail” NCT01061151 ↗ |
| Known as | TRV | “Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail” NCT01061151 ↗ |
| Route | Oral | “200 mg/300 mg orally each day after delivery” NCT01061151 ↗ |